Effect of tonsillectomy on psoriasis: A systematic review - 13/01/15
Abstract |
Background |
Streptococcal infection is associated with psoriasis onset in some patients. Whether tonsillectomy decreases psoriasis symptoms requires a systematic review of the literature.
Objective |
We sought to determine whether tonsillectomy reduces psoriasis severity through a comprehensive search of over 50 years of literature.
Methods |
We searched MEDLINE, CINAHL, Cochrane, EMBASE, Web of Science, and OVID databases (from August 1, 1960, to September 12, 2013) and performed a manual search of selected references. We identified observational studies and clinical trials examining psoriasis after tonsillectomy.
Results |
We included data from 20 articles from the last 53 years with 545 patients with psoriasis who were evaluated for or underwent tonsillectomy. Of 410 reported cases of patients with psoriasis who underwent tonsillectomy, 290 experienced improvement in their psoriasis. Although some patients who underwent tonsillectomy experienced sustained improvement in psoriasis, others experienced psoriasis relapse after the procedure.
Limitations |
Fifteen of 20 publications were case reports or series that lacked control groups. Publication bias favoring reporting improved cases needs to be considered.
Conclusion |
Tonsillectomy may be a potential option for patients with recalcitrant psoriasis associated with episodes of tonsillitis. Studies with long-term follow-up are warranted to determine more clearly the extent and persistence of benefit of tonsillectomy in psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : outcomes research, psoriasis, streptococcal infection, systematic review, tonsillectomy, tonsillitis
Plan
Funding sources: None. |
|
Disclosure: Dr Rachakonda has served as a subinvestigator for Amgen, Abbvie, and Lilly. Dr Armstrong serves as investigator and/or consultant to Abbvie, Amgen, Janssen, Lilly, Pfizer, Celgene, Novartis, UCB, Modernizing Medicine, and Merck. Dr Florek serves as a subinvestigator for Abbvie, Lilly, Janssen, Regeneron, and Novartis. Mr Dhillon has no conflicts of interest to declare. |
Vol 72 - N° 2
P. 261-275 - février 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?